Drug pricing power led by hepatitis C, diabetes and cancer

Drug pricing power led by hepatitis C, diabetes and cancer


Hepatitis C, diabetes and cancer are sustaining high pricing power through innovation according to Morningstar's…

AbbVieAntibiotics and Infectious diseasesBiogen IdecCopaxoneDiabetesGenericsGilead SciencesMerck & CoOncologyPharmaceuticalPricingTecfideraTeva Pharmaceutical IndustriesUSA

Case study draws attention to innovator brand preferences in Kenya


Some of the stronger performing brands in Kenya’s pharmaceutical market have been highlighted in a…

Antibiotics and Infectious diseasesCardio-vascularDiabetesGlaxoSmithKlineMarkets & MarketingPharmaceuticalRest of the World

$200+ billion annual opportunity in USA from using medicines more responsibly, IMS finds


Avoidable costs of more than $200 billion are incurred each year in the US health care system as a result…

Antibiotics and Infectious diseasesDiabetesFinancialGenericsHealthcareNorth AmericaPharmaceutical

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree


The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Sanofi-Aventis in licensing deal with Vivalis for MAb targeting infectious diseases and extends accord with Zealand for diabetes product


In what was another busy licensing day for French drug major Sanofi-Aventis, which since 2008 has already…

Antibiotics and Infectious diseasesDiabetesLantusLicensinglixisenatidePharmaceuticalSanofi PasteurSanofi-AventisVivalisZealand Pharma

US FDA approves Strativa’s Oravig, triggering a $20 million milestone for France’s BioAlliance; Agency could put hold on GSK


US drugmaker Strativa Pharmaceuticals says that the Food and Drug Administration has approved Oravig…

Antibiotics and Infectious diseasesAvandiaBioAlliance PharmaDiabetesGlaxoSmithKlineNorth AmericaOravigPharmaceuticalRegulationStrativa



Back to top